

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-018

APPLICATION NO.
10/043,436

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

October 9, 2002

(several sheets if necessary)

APPLICANT
Junming Le et al.

FILING DATE
January 10, 2002

GROUP
1644

U.S. PATENT DOCUMENTS

| EXAM- INER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|--------------------------|-----|-----------------|----------|-------------------|-------|---------------|----------------------------------|
| ME | AE2 | 4,816,567 | 03/28/89 | Cabilly et al. | | | |
| | AF2 | 5,075,236 | 12/24/91 | Yone et al. | | | |
| | AG2 | 5,959,087 | 09/28/99 | Rathjen et al. | | | |
| | AH2 | 5,360,716 | 11/01/94 | Ohmoto, Y. et al. | | | |

RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|--|-----|-----------------|-----------|---------|-------|---------------|-----------------------|
| | AM7 | WO92/01059 | 23 JAN 92 | PCT | | | |
| | AN7 | 02-227095 | 10 SEP 90 | JP | | | X |
| | AO7 | 61-047500 | 07 MAR 86 | JP | | | X |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|------|--|
| AT11 | Yan, L. et al., "Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha", <i>Chinese J. Biotechnology</i> , 7(2):121-126 (1991). |
| AU11 | Mateo, C. et al., "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity", <i>Hybridoma</i> , 19(6):463-471 (2000). |
| AV11 | Paul, W.E. (Ed.), <i>Fundamental Immunology</i> , 3 rd Edition, Pub. Raven Press Ltd., pp. 292-293 (1993). |
| AW11 | Borrebaeck, C.A.K. (Ed.), <i>Antibody Engineering</i> , 2 nd Edition, Pub. Oxford University Press, p. 291 (1995). |
| AX11 | Socher, S. et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor", <i>Proc. Natl. Acad. Sci., USA</i> 84:8829-8833 (1987). |
| AY11 | Goh, C., "Tumour Necrosis Factors in Clinical Practice", <i>Annals of the Academy of Medicine</i> , 19(2):235-239 (1990). |

EXAMINER

PHU P B L M B Z

DATE CONSIDERED

9/29/04

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are enclosed except those entered in prior applications, U.S. Application No. 09/927,703, to which priority under 35 U.S.C. 120 is claimed. The earlier applications contains copies of the cited references.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☒ The "concise explanation" requirement (non-English references) for references AN7 and AO7 under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☒ the enclosed English language abstracts and also reference AH2, which is a U.S. equivalent of AN7. Copies of references AH2, AN7 and AO7 are enclosed in prior application U.S. Application No. 09/927,703 to which priority under 35 U.S.C. 120 is claimed.

- ☒ Applicant requests that the following pending applications be considered:

Examiner's
Initials

PL

U.S. Patent Application No. 10/227,488, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed August 23, 2002, Docket No.: 0975.1005-025

Philip J. Gmora
Examiner

9/29/04
Date

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are enclosed except those entered in prior applications, U.S. Application No. 09/927,703, U.S. Application No: 09/756,398 and U.S. Application No: 09/133,119 to which priority under 35 U.S.C. 120 is claimed. The earlier applications contains copies of the cited references.
- ☒ Some of the listed references were cited in the enclosed International Search Report and European Search Report in a counterpart foreign application. [ISR References AS, AV, AU, AZ, AX7, AY7 and AZ7; ESR References AP2, AM3, AN3, AO3, AP3, AQ3 and AL5]
- ☐ The "concise explanation" requirement (non-English references) for reference(s) ☐ under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.

- ☒ Applicant requests that the following pending applications be considered:

Examiner's
Initials

[Signature]

Patent Counsel 2/29/04

U.S. Patent Application No. 09/756,398, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-006

[Signature]

U.S. Patent Application No. 09/756,301, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-008

U.S. Patent Application No. 09/766,535, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 18, 2001, Docket No.: 0975.1005-010

U.S. Patent Application No. 09/897,724, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 2, 2001, Docket No.: 0975.1005-012

U.S. Patent Application No. 09/927,703, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed August 10, 2001, Docket No.: 0975.1005-013

U.S. Patent Application No. 10/010,229, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed December 7, 2001, Docket No.: 0975.1005-014

U.S. Patent Application No. 10/043,450, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-015

U.S. Patent Application No. 10/044,534, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-016

U.S. Patent Application No. 10/043,432, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-017

U.S. Patent Application No. 10/176,460, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 20, 2002, Docket No.: 0975.1005-019

U.S. Patent Application No. 10/187,121, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-020

U.S. Patent Application No. 10/186,559, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-021

U.S. Patent Application No. 10/198,845, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 18, 2002, Docket No.: 0975.1005-022

U.S. Patent Application No. 10/200,795, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 22, 2002, Docket No.: 0975.1005-023

Phuc Gama 2/29/04

pl
U.S. Patent Application No. 10/208,195, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 29, 2002, Docket No.: 0975.1005-024

Philip Camber
Examiner

9/29/04
Date

☒ [X] The specification for the above cited co-pending applications is identical to the present specification (10/043,436). Therefore, only a copy of the current claims for each application is enclosed. Copies of the specifications of the co-pending applications will be provided upon request.

☐ [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.






Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By *Deirdre E. Sanders*
Deirdre E. Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated: *September 19, 2002*

| PTO-149 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 19, 2002 (Use several sheets if necessary) | | | | ATTORNEY DOCKET NO. 0975.1005-018 | | APPLICATION NO. 10/043,436 | |
|---|---------------------------------|--|-----------|--------------------------------------|-------|---|---|
| | | | | APPLICANT Junming Le et al. | |  | |
| | | | | FILING DATE January 10, 2002 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM- INER INI- TIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|  | AA | 4,603,106 | 07/29/86 | Cerami et al. | 435 | 7 |  |
| | AB | 4,822,776 | 04/18/89 | Cerami et al. | 514 | 21 | |
| | AC | 5,658,570 | 08/19/97 | Newman et al. | 424 | 184.1 | |
| | AD | 5,750,105 | 5/12/98 | Newman et al. | 424 | 133.1 | |
| | AE | 5,231,024 | 7/27/93 | Moeller et al. | 435 | 240.27 | |
| | AF | 5,223,395 | 06/29/93 | Gero | 435 | 71 | |
| | AG | 5,436,154 | 07/25/95 | Barbanti et al. | 435 | 240.27 | |
| | AH | 5,654,407 | 08/05/97 | Boyle et al. | 530 | 388.15 | |
| | AI | 5,700,788 | 12/23/97 | Mongelli et al. | 514 | 91 | |
| | AJ | 5,730,975 | 03/24/98 | Hotamisligil et al. | 424 | 130.1 | |
| | AK | 5,741,488 | 04/21/98 | Feldman et al. | 424 | 154.1 | |
| | FOREIGN PATENT DOCUMENTS | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
| | AL | 0 212 489 A2 | 04 MAR 87 | EPO | | | |
| | AM | 0 218 868 A2 | 22 APR 87 | EPO | | | |
| | AN | 0 288 088 A2 | 26 OCT 88 | EPO | | | |
| | AO | 0 308 378 A2 | 22 MAR 89 | EPO | | | |
| | AP | 0 380 068 A1 | 01 AUG 90 | EPO | | | |
| | AQ | 0 393 438 A3 | 24 OCT 90 | EPO | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AR | Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," <i>Nature</i> , 316:552-554 (1985). | | | | | |
| | AS | Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," <i>Science</i> , 229:869-871 (1985). | | | | | |
|  | AT | Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> , 229:1202-1207 (1985). | | | | | |
| EXAMINER  | | | | DATE CONSIDERED 9/19/04 | | | |

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-018APPLICATION NO.
10/043,461 PINFORMATION DISCLOSURE CITATION
IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

APPLICANT
Junming De et al.FILING DATE
January 10, 2002GROUP
1644

SEP 23 2002

U.S. PATENT DOCUMENTS

| EXAM- INER INI- TIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|-------------------------------|-----|-----------------|----------|---------------------|-------|---------------|----------------------------------|
| M | AA2 | 5,776,947 | 07/07/98 | Kroemer et al. | 514 | 312 | TECH CENTER 1600/2900 |
| | AB2 | 6,015,558 | 01/18/00 | Hotamisligil et al. | 424 | 142.1 | SEP 8 2002 |
| | AC2 | 6,172,202 B1 | 01/09/01 | Marcucci et al. | 530 | 406 | |
| | AD2 | 6,194,451 B1 | 02/27/01 | Alpegiani et al. | 514 | 459 | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|--|-----|-----------------|-----------|---------|-------|---------------|-----------------------|
| | AL2 | 0 398 327 A1 | 22 NOV 90 | EPO | | | |
| | AM2 | 0 412 486 A1 | 13 FEB 91 | EPO | | | |
| | AN2 | 0 433 900 A1 | 26 JUN 91 | EPO | | | |
| | AO2 | 0 526 905 A2 | 10 FEB 93 | EPO | | | |
| | AP2 | WO91/02078 | 21 FEB 91 | PCT | | | |
| | AQ2 | WO92/07076 | 30 APR 92 | PCT | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


| | | |
|---|----|---|
| | AU | Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. & Biophys. Res. Comm.</i> , 137(2):847-854 (1986). |
| | AV | Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987). |
| | AW | Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987). |
| | AX | Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987). |
| M | AY | Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987). |





EXAMINER




P. H. W. G. G. G.

DATE CONSIDERED

9/29/04

| | | | | | | | |
|--|-----|---|-----------|---|-------|---------------|----------------------------------|
| PTO-1449 REPRODUCED | | ATTORNEY DOCKET NO. 0975.1005-018 | | APPLICATION NO. 10/043,436 | | | |
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION. September 19, 2002 (Use several sheets if necessary) | | APPLICANT Junming Le et al. | |  | | | |
| | | FILING DATE January 10, 2002 | | | | GROUP 1644 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM- INER INI- TIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
| | AL3 | WO 92/13095 | 06 AUG 92 | PCT | | | |
| | AM3 | 0 260 610 A2 | 23 MAR 88 | EPO | | | |
| | AN3 | 91/09967 | 11 JUL 91 | PCT | | | |
| | A03 | 0 351 789 A2 | 24 JAN 90 | EPO | | | |
| | AP3 | 0 350 690 A2 | 17 JAN 90 | EPO | | | |
| | AQ3 | 90/00902 | 08 FEB 90 | PCT | | | |
| | AL4 | WO 92/11383 | 09 JUL 92 | PCT | | | |
| | AM4 | WO 93/02108 | 04 FEB 93 | PCT | | | |
| | AN4 | WO 92/16553 | 19 MAR 92 | PCT | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AZ | Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987). | | | | | |
| | AR2 | Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987). | | | | | |
| | AS2 | Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988). | | | | | |
| | AT2 | Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988). | | | | | |
| | AU2 | Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988). | | | | | |
| | AV2 | Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, Abstracts of Annual Meeting 1989. | | | | | |
| EXAMINER <i>Robert G. Meyer</i> | | | | DATE CONSIDERED <i>9/19/04</i> | | | |

| | | | | | | | |
|--|-------------|--|-----------|---------------------------------|-------|--|----------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 19, 2002 (Use several sheets if necessary) | | ATTORNEY DOCKET NO. 0975.1005-018 | | APPLICATION NO. 10/043,436 | | <div style="text-align: center;">  </div> | |
| | | APPLICANT Junming Le et al. | | FILING DATE January 10, 2002 | | GROUP 1644 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM- INER INI- TIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|  | AO4 | WO 91/09967 | 11 JUL 91 | PCT | | | |
| | AP4 | 0 486 526 B2 | 07 MAR 01 | EPO | | | |
| | AQ4 | WO 92/02190 | 10 JUN 92 | PCT | | | |
| | AL5 | 0 288 088 B1 | 26 OCT 88 | EPO | | | |
| | AM5 | 0 351 789 B1 | 24 JAN 90 | EPO | | | |
| | AN5 | 0 453 898 A2 | 30 OCT 91 | EPO | | | X |
| | AO5 | 0 585 705 A1 | 09 MAR 94 | EPO | | | |
| | AP5 | 0 614 984 A2 | 14 SEP 94 | EPO | | | |
| | AQ5 | 0 663 836 B1 | 26 JUL 95 | EPO | | | |
| | AL6 | WO 89/08460 | 21 SEP 89 | PCT | | | |
| AM6 | WO 90/01950 | 08 MAR 90 | PCT | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AW2 | Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society</i> , Abstract 184, p. 50 (1989). | | | | | |
| | AX2 | Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor α /Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," <i>J of Exp Med.</i> , 169:2021-2027 (1989). | | | | | |
|  | AY2 | Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989). | | | | | |
| | | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
|  | | | | 9/29/04 | | | |

| | | | | | | | |
|---|-----|---|-----------|---|-------|---------------|----------------------------------|
| PTO-1449 REPRODUCED | | ATTORNEY DOCKET NO. 0975.1005-018 | | APPLICATION NO. 10/043,436 | | | |
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 19, 2002 (Use several sheets if necessary) | | APPLICANT Junning Le et al. | |  | | | |
| | | FILING DATE January 10, 2002 | | | | GROUP 1644 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM- INER INI- TIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|  | AN6 | WO 91/04054 | 04 APR 91 | PCT | | | |
| | AO6 | WO 92/01472 | 06 FEB 92 | PCT | | | |
| | AP6 | WO 93/11236 | 10 JUN 93 | PCT | | | |
| | AQ6 | WO 94/08609 | 28 APR 94 | PCT | | | |
| | AL7 | WO 94/08619 | 28 APR 94 | PCT | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AZ2 | Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989). | | | | | |
| | AR3 | Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989). | | | | | |
| | AS3 | Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990). | | | | | |
| | AT3 | Herve, P. et al., "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," Abstract 3.25, <i>Lymphoma Res.</i> 9:591 (1990). | | | | | |
| | AU3 | Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- α in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990). | | | | | |
| | AV3 | Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious Diseases</i> , 161:1148-1152 (1990). | | | | | |
| | AW3 | Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990). | | | | | |
|  | AX3 | Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF- α monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990). | | | | | |
| EXAMINER PHILIP GAMBLER | | | | DATE CONSIDERED 9/29/04 | | | |

TECH CENTER 1600/2900

SEP 30 2002

OTPE
SEP 23 2002
PATENT & TRADEMARK OFFICE

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-018APPLICATION NO.
10/043,436 EINFORMATION DISCLOSURE CITATION
IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

APPLICANT
Junming Le et al.FILING DATE
January 10, 2002GROUP
1644

U.S. PATENT DOCUMENTS

| EXAM- INER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|--------------------------|-----------------|------|------|-------|---------------|----------------------------------|
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|-----------------|------|---------|-------|---------------|-----------------------|
| | | | | | |
| | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----|-----|--|
| me | AY3 | Hinshaw, L.B. et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292 (1990). |
| | AZ3 | Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990). |
| | AR4 | Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990). |
| | AS4 | Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990). |
| | AT4 | Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990). |
| | AU4 | Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990). |
| | AV4 | Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990). |
| | AW4 | Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990). |
| | AX4 | Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990). |
| PO | AY4 | Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990). |


EXAMINER

Phuoc Gamber

DATE CONSIDERED


9/29/04

| | | | |
|---|-----|--|---------------------------|
| PTO-1449 REPRODUCED | | ATTORNEY DOCKET NO. 0975.1005-018 | APPLICATION NO. 10/043 |
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 19, 2002 (Use several sheets if necessary) | | APPLICANT Junming Le et al. | |
| | | FILING DATE January 10, 2002 | GROUP 1644 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| MP | AZ4 | Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," <i>J. of Immunological Methods</i> , 140:37-43 (1991). | |
| | AR5 | Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991). | |
| | AS5 | Aderka, Dan et al., "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," <i>Israel J. Med. Sci.</i> , 28(2):126-130 (1992). | |
| | AT5 | Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," <i>ASM News</i> , 58(9):479-482 (1992). | |
| | AU5 | Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," <i>TBTECH</i> , 11:42-44 (1993). | |
| | AV5 | Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," <i>N.E. Journal of Medicine</i> , 328(20):1471-1477 (1993). | |
| | AW5 | Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985). | |
| | AX5 | Beutler, B. et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i> , 161:984-995 (1985). | |
| | AY5 | Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990). | |
| | AZ5 | Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," 4Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991). | |
| | AR6 | Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991). | |
| | AS6 | Genbank Accession, No. N90300 (1989, November 1). | |
| | AT6 | Genbank Accession, No. M32046 (1990, June 15). | |
| | AU6 | Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies", <i>Behring Inst. Mitt</i> , No.78:118-132 (1985). | |
| | AV6 | Whittle, Nigel, et al., "Construction and Expression of a CDR-Grafted Anti-TNF Antibody," <i>J. Cell Biochem, Supl.</i> 13A:96 (1989). | |
| | AW6 | Gorman, S.D. and Clark, M.R., "Humanisation of monoclonal antibodies for therapy," <i>Sem Immunol</i> , 2:457-466 (1990). | |
| MP | AX6 | Starnes, H. Fletcher, Jr., et al., "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal <i>Escherichia Coli</i> Infection and Lethal Tumor Necrosis Factor Challenge in Mice," <i>J Immunol</i> , 145:4185-4191 (1990). | |
| EXAMINER | | DATE CONSIDERED | |
| P. H. G. 61 MBR | | 9/22/04 | |

| | | |
|--|---|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 19, 2002 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 0975.1005-018 APPLICANT Junming Le et al. FILING DATE January 10, 2002 | APPLICATION NO. 10/043,436 GROUP 1644  |
|--|---|--|

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-------------------------|---|
| AY6 | Duncombe, Andrew S. et al., "Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia," <i>J Immunol</i> , 143:3828-3834 (1989). |
| AZ6 | Aderka, Dan et al., "IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice," <i>J Immunol</i> , 143:3517-3523 (1989). |
| AR7 | Aderka, Dan, "Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications," <i>Isr J Med Sci</i> , 27:52-60 (1991). |
| AS7 | Lassalle, Ph., et al., "Potential Implication of Endothelial Cells in Bronchial Asthma," <i>Int Arch Allergy Appl Immunol</i> , 94:233-238 (1991). |
| AT7 | Fong, Yuman and Lowry, Stephen F., "Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis," <i>Clin Immunol Immunopathol</i> , 55:157-170 (1990). |
| AU7 | Eck, Michael J. and Sprang, Stephen R., "The Structure of Tumor Necrosis Factor- α at 2.6 Å Resolution," <i>J Biol Chem</i> , 264:17595-17605 (1989). |
| AV7 | Gillies, Stephen D. et al., "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," <i>J Immunol Methods</i> , 125:191-202 (1989). |
| AW7 | Kameyama, Koh-zoh, et al., "Convenient plasmid vectors for construction of chimeric mouse/human antibodies," <i>FEBS Lett</i> , 244:301-306 (1989). |
| AX7 | Hayashi, H. et al., "An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," <i>Recent Adv. Chemother</i> , 820-821 (1985). |
| AY7 | Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J Immunol Methods</i> , 96:57-62 (1987). |
| AZ7 | Sunahara, N. et al., "Simple enzyme immunoassay methods for recombinant human tumor necrosis factor α and its antibodies using a bacterial cell wall carrier," <i>J Immunol Methods</i> , 109:203-214 (1988). |
| AR8 | Oliff, A., et al., "Tumors Secreting Human TNF/Cachectin Induce Cachexia in Mice," <i>Cell</i> , 50:555-563 (1987). |
| AS8 | Mule, J.J., et al., "Antitumor Activity of Recombinant Interleukin 6 in Mice," <i>The Journal of Experimental Medicine</i> , 171:629-636 (1990). |
| AT8 | Luettig, B., et al., "Evidence For The Existence Of Two Forms Of Membrane Tumor Necrosis Factor: An Integral Protein And A Molecule Attached To Its Receptor," <i>The Journal of Immunology</i> , 143:4034-4038 (1989). |
| EXAMINER P. H. 61m92 | DATE CONSIDERED 9/29/04 |

| | | |
|--|---|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 19, 2002 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 0975.1005-018 APPLICANT Junming Le et al. FILING DATE January 10, 2002 | APPLICATION NO. 10/043,426 GROUP 1644  |
|--|---|--|

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----------|----------------------------|--|
| m | AU8 | Barbuto, J.A.M., et al "Production of neutralizing antibodies to tumor necrosis factor by human tumor-infiltrating B lymphocytes," <i>Proceedings of the American Association for Cancer Research</i> , 34:487, Abstract 2904, (1993). |
| | AV8 | Bendtzen, K., et al., "Auto-Antibodies To IL-1 α and TNF α In Normal Individuals And In Infectious And Immunoinflammatory Disorders," <i>The Physiological and Pathological Effects of Cytokines</i> , 10B:447-452 (1990). |
| | AW8 | Fomsgaard, A., et al., "Auto-Antibodies To Tumour Necrosis Factor α In Healthy Humans And Patients With Inflammatory Diseases And Gram-Negative Bacterial Infections," <i>Scand. J. Immunol.</i> , 30:219-223 (1989). |
| | AX8 | James, K. and Bell, G.T., "Human Monoclonal Antibody Production Current Status And Future Prospects," <i>Journal of Immunological Methods</i> , 100:5-40 (1987). |
| | AY8 | Alberts, B. et al., <i>Molecular Biology of the Cell</i> , Garland Publishing Inc., pp 182-183 (1983). |
| | AZ8 | Simpson, S.Q., et al., "Role Of Tumor Necrosis Factor In Sepsis And Acute Lung Injury," <i>Critical Care Clinics</i> , 5:27-47 (1989). |
| | AR9 | Bendtzen, K., et al., "Native inhibitors (autoantibodies) of IL-1 α and TNF," <i>Immunology Today</i> , 10(7):222 (1989). |
| | AS9 | Davenport, C., et al., "Stimulation Of Human B Cells Specific For <i>Candida Albicans</i> For Monoclonal Antibody Production," <i>FEMS Microbiol Immunol</i> , 4(6):335-343 Abstract (1992). |
| | AT9 | Pennica, D., et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> , 312(20/27):724-729 (1984). |
| | AU9 | Gray, P.W., et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," <i>Nature</i> , 312(20/27):721-724 (1984). |
| | AV9 | Petersen, C.M., et al., "Bioactive human recombinant tumor necrosis factor- α : an unstable dimer?," <i>Eur. J. Immunol.</i> , 19:1887-1894 (1989). |
| | AW9 | Smith, C. A., et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," <i>Science</i> , 248:1019-1023 (1990). |
| | AX9 | Brennan, F.M., et al., "Inhibitory Effect Of TNF α Antibodies On Synovial Cell Interleukin-1 Production In Rheumatoid Arthritis," <i>The Lancet</i> , 244-247 (1989). |
| B | AY9 | Hahn, T., et al., "Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein," <i>Proc. Natl. Acad. Sci. USA</i> 82:3814-3818 (1985). |
| EXAMINER | DATE CONSIDERED 9/29/04 | |

PTO 1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-018APPLICATION NO.
10/043,436INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

September 19, 2002

APPLICANT
Junming Le et al.FILING DATE
January 10, 2002GROUP
1644

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|---------------|------|--|
| M | AZ9 | Grau, G.E., et al., "Tumor Necrosis Factor (Cachectin) as an Essential Mediator in Murine Cerebral Malaria," <i>Science</i> , 237:1210-1212 (1987). |
| | AR10 | Barbanti, E., et al., "A high-affinity neutralizing anti-human TNF-alpha monoclonal antibody that cross-reacts with human TNF-beta," <i>Abstracts</i> , March 6th-9th (1991). |
| | AS10 | Jones, E.Y., et al., "Structure of tumour necrosis factor," <i>Nature</i> , 338:225-228 (1989). |
| | AT10 | Clark, W. R., "Types of Antibody Reactions," In <i>The Experimental Foundations of Modern Immunology</i> , (NY: John Wiley & Sons, Inc.) 4th Ed., pp 143-155 (1991). |
| | AU10 | Beutler, B., et al., "Cachectin and tumour necrosis factor as two sides of the same biological coin," <i>Nature</i> , 320:584-588 (1986). |
| | AV10 | Folks, T. M., et al., "Tumor Necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone," <i>Proc. Natl. Acad. Sci. USA</i> , 86:2365-2358 (1989). |
| | AW10 | Hird, V., et al., "Immunotherapy with Monoclonal Antibodies," In <i>Genes and Cancer</i> (John Wiley & Sons, Ltd.) (1990). <i>PAGES 183-189</i> |
| | AX10 | Rhein, R., "Another sepsis drug down-Immunex' TNF receptor," <i>Biotechnology Newswatch</i> , Monday, October 4, 1993, pp. 1,3. |
| | AY10 | Boyle, P., et al., "A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- α ," <i>Cellular Immunology</i> , 152:556-568 (1993). |
| | AZ10 | Boyle, P., et al., "The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF α on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," <i>Cellular Immunology</i> , 152:569-581 (1993). |
| r | AR11 | Sheehan, K.C.F., et al., "Generation And Characterization Of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors," <i>The Journal of Immunology</i> , 142(11):3884-3893 (1989). |
| M | AS11 | Jacob, C.O., et al., "Tumour necrosis factor- α in murine autoimmune 'lupus' nephritis," <i>Nature</i> , 331:356-358 (1988). |
| | | |
| | | |
| | | |
| | | |
| EXAMINER | | DATE CONSIDERED |
| PHILIP GIMBER | | 9/24/04 |